BioNTech | 6-K: Pfizer and BioNtech Provide Update on mRNA-Based Combination Vaccine Program Against Influenza and Covid-19 in Individuals 18-64 Years of Age
BioNTech | 6-K: Pfizer and BioNtech Provide Update on mRNA-Based Combination Vaccine Program Against Influenza and Covid-19 in Individuals 18-64 Years of Age
BioNTech | 6-K：輝瑞和 BioNTech 提供基於 mRNA 的針對 18-64 歲人群的流感和 COVID-19 聯合疫苗計劃的最新情況
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。